Editors: Ken Herrmann, MD, MBA; Steven M. Larson, MD; and Wolfgang A. Weber, MD
The past year has seen unprecedented progress in the field of nuclear theranostics, particularly for treatment of neuroendocrine tumors and advanced prostate cancer. Against the backdrop of these recent successes, this publication of The Journal of Nuclear Medicine offers a detailed overview of targeted radionuclide therapy in thyroid cancer, neuroendocrine tumors, and prostate cancer and summarizes other applications of nuclear theranostics—as well as new developments on the horizon.
Non-Member Price: $63.00
Member Price: $45.00